Sector
PharmaceuticalsOpen
₹3.75Prev. Close
₹3.8Turnover(Lac.)
₹0.37Day's High
₹3.75Day's Low
₹3.6552 Week's High
₹052 Week's Low
₹0Book Value
₹-9.83Face Value
₹10Mkt Cap (₹ Cr.)
7.06P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2012 | Mar-2011 | Mar-2010 | Mar-2009 |
---|---|---|---|---|
Equity Capital | 276.67 | 19.34 | 19.34 | 28.64 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -38.36 | 269.13 | 337.94 | 243.01 |
Net Worth | 238.31 | 288.47 | 357.28 | 271.65 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2012 | Mar-2011 |
---|---|---|
Revenue | 151.48 | 824.84 |
yoy growth (%) | -81.63 | |
Raw materials | -113.18 | -616.41 |
As % of sales | 74.71 | 74.73 |
Employee costs | -18.8 | -20.44 |
Y/e 31 Mar( In .Cr) | Mar-2012 | Mar-2011 |
---|---|---|
Profit before tax | -152.1 | -46.76 |
Depreciation | -66.03 | -60.79 |
Tax paid | -19.02 | -22.04 |
Working capital | -269.65 | |
Other operating items |
Y/e 31 Mar | Mar-2012 | Mar-2011 |
---|---|---|
Growth matrix (%) | ||
Revenue growth | -81.63 | |
Op profit growth | -120.84 | |
EBIT growth | -226.63 | |
Net profit growth | 346.88 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,788.8 | 136.25 | 4,29,217.03 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,924.5 | 75.78 | 1,57,100.32 | 594 | 0.51 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,533.7 | 26.61 | 1,23,852.12 | 1,438.15 | 0.85 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,332.4 | 61.86 | 1,12,844.49 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,545.5 | 54.3 | 1,05,003.3 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Purnandu Jain
Whole Time Executive Director
Girraj Vijayvargiya
Director
Dileep Shinde
Director
Clifton Zimmermann
Company Secretary
S C Rane
Director
Ramesh Batham
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ankur Drugs & Pharma Ltd
Summary
Ankur Drugs and Pharma Ltd is engaged in contract manufacturing of pharmaceuticals formulations. The company has three manufacturing units: two in Himachal Pradesh and one in Daman. Its business segment includes pharmaceutical formulations in the form of tablets, capsules, liquid orals, oral powder, dry syrups, ointments, insta use suspension, form fill and seal (FFS), liquid injectables and dry powder injectables. Its clients include Ranbaxy Laboratories Limited, Cipla Limited, Sandoz Private Limited, Abbott India Limited, USV Limited, Plizer Limited and Sanofi Aventis.The company is a public limited company listed at Bombay Stock Exchange and National Stock Exchange of India Limited. The company was incorporated in the year 1995.Ankur has to its credit several distinctions. Its in the forefront of contract manufacturing with Indias leading and multinational pharmaceutical companies. Ankurs first plant is situated at Daman, which is having dedicated block for General and Betalactum products in oral dosage form.The Company has set-up two plants spread across dimensions at Himachal Pradesh in excise and pollution free zone, amongst lush green surroundings. The main object behind setting up two units was to cater Domestic and International Market.The companys 400 different formulations of various dosage forms i.e. Tablets, Capsules, Dry Syrups, Liquid Orals, Injectables, Oinments, etc. are currently manufactured in Ankurs multi location manufacturing facilities. Company has alr
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.